CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
CTMX Stock Chart & Stats
$4.56
-$0.06(-5.83%)
At close: 4:00 PM EST
$4.56
-$0.06(-5.83%)
Day’s Range― - ―
52-Week Range$0.40 - $8.21
Previous CloseN/A
Volume1.08M
Average Volume (3M)9.87M
Market Cap
$985.77M
Enterprise Value$767.92M
Total Cash (Recent Filing)$137.05M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Apr 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding216,177,300
10 Day Avg. Volume5,805,878
30 Day Avg. Volume9,865,104
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.93
Price to Sales (P/S)7.71
P/FCF Ratio-7.75
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue10.08
Enterprise Value/Gross Profit10.15
Enterprise Value/Ebitda-39.60
Forecast
1Y Price Target
$13.67Price Target Upside199.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$21.48M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1 dose‑expansion results for Varseta‑M showed confirmed tumor responses and durable progression benefit that appear meaningfully above late‑line colorectal cancer benchmarks, supporting potential for earlier‑line consideration if efficacy holds.
Commercial OpportunityA masked EpCAM antibody‑drug conjugate profile positions Varseta‑M as a potentially rare ADC with a large commercial opportunity in later‑line colorectal cancer and scope to expand into other EpCAM‑expressing tumor types.
Platform DifferentiationThe Probody Technology Platform's tumor‑targeting approach may enable treatment of previously undruggable targets while limiting off‑target effects, enhancing program differentiation if clinical validation continues.
Bears Say
Data UncertaintySmall patient numbers and limited follow‑up create substantial uncertainty, requiring larger cohorts and longer follow‑up to validate early signals and reduce program risk.
Financial And Rating RiskA constrained cash runway combined with a Neutral analyst stance implies the stock could face significant downside pressure if upcoming clinical readouts disappoint or additional financing is needed.
Safety ProfileSerious adverse events, including kidney injury and colitis, together with persistent high rates of severe diarrhea, raise material safety concerns that could restrict labeling and commercial uptake even if efficacy is confirmed.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was $0.40 and its highest was $8.21 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
CytomX Therapeutics Inc’s market cap is $985.77M.
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Apr 30, 2026 which is in 24 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Mar 16, 2026. The company reported -$0.173 earnings per share for the quarter, missing the consensus estimate of -$0.093 by -$0.08.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 216,177,300 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of -$0.173 in its last earnings report, missing expectations of -$0.093. Following the earnings report the stock price went up 44.231%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (199.78% Upside)
$13.67 (199.78% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
650.00%
12-Months-Change
Fundamentals
Return on Equity
-19.77%
Trailing 12-Months
Asset Growth
24.35%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CTMX Company Deck
CTMX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive — The call presented robust and clinically meaningful efficacy signals (ORR up to 32%, median PFS 6.8–7.1 months), compelling target validation, and clear reductions in the main severe toxicity (grade 3 diarrhea) through a combined strategy of AIBW dosing and dual prophylaxis. Remaining risks are primarily the need for larger/mature data (optimization cohorts, OS), ongoing management of diarrhea/electrolyte events, and confirmation of these early safety gains in bigger populations and combinations. Overall, the highlights materially outweigh the lowlights and support an optimistic near-term development trajectory.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$13.67
▲(199.78% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
Arcturus Therapeutics
―
KalVista Pharmaceuticals
―
Bicycle Therapeutics
―
Ownership Overview
1.36% Insiders
17.48% Mutual Funds
44.13% Other Institutional Investors
28.32% Public Companies and Individual Investors